Loomis, Sayles & Company’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.41M | Buy |
4,800
+2,060
| +75% | +$2.09M | 0.01% | 423 |
|
|
2025
Q4 | $2.94M | Buy |
2,740
+1,002
| +58% | +$958K | ﹤0.01% | 444 |
|
|
2025
Q3 | $1.33M | Buy |
1,738
+3
| +0.2% | +$2.23K | ﹤0.01% | 475 |
|
|
2025
Q2 | $1.35M | Sell |
1,735
-392
| -18% | -$305K | ﹤0.01% | 477 |
|
|
2025
Q1 | $1.76M | Sell |
2,127
-100
| -4% | -$83.2K | ﹤0.01% | 453 |
|
|
2024
Q4 | $1.72M | Buy |
2,227
+358
| +19% | +$296K | ﹤0.01% | 447 |
|
|
2024
Q3 | $1.66M | Buy |
1,869
+370
| +25% | +$333K | ﹤0.01% | 439 |
|
|
2024
Q2 | $1.36M | Buy |
1,499
+231
| +18% | +$185K | ﹤0.01% | 453 |
|
|
2024
Q1 | $986K | Buy |
1,268
+243
| +24% | +$173K | ﹤0.01% | 460 |
|
|
2023
Q4 | $597K | Sell |
1,025
-44
| -4% | -$25.7K | ﹤0.01% | 459 |
|
|
2023
Q3 | $574K | Buy |
1,069
+817
| +324% | +$421K | ﹤0.01% | 463 |
|
|
2023
Q2 | $118K | Sell |
252
-15
| -6% | -$6.29K | ﹤0.01% | 537 |
|
|
2023
Q1 | $92K | Buy |
267
+147
| +123% | +$49.6K | ﹤0.01% | 547 |
|
|
2022
Q4 | $44K | Buy |
120
+33
| +38% | +$11.7K | ﹤0.01% | 625 |
|
|
2022
Q3 | $28K | Sell |
87
-2
| -2% | -$634 | ﹤0.01% | 597 |
|
|
2022
Q2 | $29K | Sell |
89
-4
| -4% | -$1.2K | ﹤0.01% | 573 |
|
|
2022
Q1 | $27K | Sell |
93
-58
| -38% | -$14.9K | ﹤0.01% | 612 |
|
|
2021
Q4 | $42K | Sell |
151
-62
| -29% | -$15.7K | ﹤0.01% | 618 |
|
|
2021
Q3 | $49K | Buy |
213
+44
| +26% | +$10.9K | ﹤0.01% | 591 |
|
|
2021
Q2 | $39K | Buy |
169
+6
| +4% | +$1.21K | ﹤0.01% | 597 |
|
|
2021
Q1 | $30K | Sell |
163
-8,962
| -98% | -$1.75M | ﹤0.01% | 603 |
|
|
2020
Q4 | $1.54M | Buy |
9,125
+2,195
| +32% | +$328K | ﹤0.01% | 456 |
|
|
2020
Q3 | $1.03M | Sell |
6,930
-173
| -2% | -$26.8K | ﹤0.01% | 446 |
|
|
2020
Q2 | $1.17M | Sell |
7,103
-851
| -11% | -$131K | ﹤0.01% | 434 |
|
|
2020
Q1 | $1.1M | Buy |
7,954
+3,217
| +68% | +$442K | ﹤0.01% | 444 |
|
|
2019
Q4 | $623K | Sell |
4,737
-6,514
| -58% | -$755K | ﹤0.01% | 491 |
|
|
2019
Q3 | $1.26M | Buy |
+11,251
| New | +$1.25M | ﹤0.01% | 482 |
|
|
2019
Q1 | – | Sell |
-27,971
| Closed | -$3.24M | – | 830 |
|
|
2018
Q4 | $3.24M | Sell |
27,971
-80,434
| -74% | -$8.99M | 0.01% | 452 |
|
|
2018
Q3 | $11.6M | Sell |
108,405
-223,943
| -67% | -$22.4M | 0.02% | 344 |
|
|
2018
Q2 | $28.4M | Sell |
332,348
-125,590
| -27% | -$10.3M | 0.06% | 165 |
|
|
2018
Q1 | $35.4M | Sell |
457,938
-5,227
| -1% | -$421K | 0.08% | 127 |
|
|
2017
Q4 | $39.1M | Sell |
463,165
-78,508
| -14% | -$6.68M | 0.08% | 119 |
|
|
2017
Q3 | $46.3M | Sell |
541,673
-15,421
| -3% | -$1.26M | 0.1% | 106 |
|
|
2017
Q2 | $45.8M | Sell |
557,094
-99,789
| -15% | -$8.14M | 0.11% | 99 |
|
|
2017
Q1 | $55.3M | Sell |
656,883
-213,093
| -24% | -$17.1M | 0.14% | 89 |
|
|
2016
Q4 | $64M | Sell |
869,976
-71,366
| -8% | -$5.31M | 0.16% | 84 |
|
|
2016
Q3 | $75.6M | Sell |
941,342
-243,156
| -21% | -$19.5M | 0.19% | 64 |
|
|
2016
Q2 | $93.3M | Buy |
1,184,498
+22,956
| +2% | +$1.73M | 0.25% | 50 |
|
|
2016
Q1 | $83.6M | Buy |
1,161,542
+13,345
| +1% | +$1.01M | 0.24% | 57 |
|
|
2015
Q4 | $96.7M | Buy |
1,148,197
+59,635
| +5% | +$4.95M | 0.27% | 51 |
|
|
2015
Q3 | $91.1M | Buy |
1,088,562
+145,543
| +15% | +$12.3M | 0.27% | 55 |
|
|
2015
Q2 | $78.7M | Sell |
943,019
-180,316
| -16% | -$13.7M | 0.22% | 78 |
|
|
2015
Q1 | $81.6M | Sell |
1,123,335
-279,881
| -20% | -$19.9M | 0.23% | 80 |
|
|
2014
Q4 | $96.8M | Sell |
1,403,216
-339,244
| -19% | -$22.9M | 0.27% | 66 |
|
|
2014
Q3 | $113M | Sell |
1,742,460
-90,073
| -5% | -$5.7M | 0.33% | 59 |
|
|
2014
Q2 | $114M | Sell |
1,832,533
-91,857
| -5% | -$5.48M | 0.32% | 67 |
|
|
2014
Q1 | $113M | Buy |
1,924,390
+3,549
| +0.2% | +$198K | 0.32% | 72 |
|
|
2013
Q4 | $98M | Buy |
+1,920,841
| New | +$96.2M | 0.29% | 83 |
|
Other funds holding LLY
VCM
VPM
Loomis, Sayles & Company's LLY Position: Q1 2026 in Review
Loomis, Sayles & Company increased its Eli Lilly (LLY) stake by 75% in Q1 2026, buying an estimated $2.09M and bringing the position to 4,800 shares worth $4.41M. The position accounts for 0.01% of the portfolio, ranked #423.
Loomis, Sayles & Company first reported a position in LLY in Q4 2013 and has held it in 48 quarters since. The position peaked at $114M in Q2 2014. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Loomis, Sayles & Company held 4,800 shares of Eli Lilly worth $4.41M as of Q1 2026.
- Loomis, Sayles & Company bought 2,060 Eli Lilly shares in Q1 2026, an estimated $2.09M.
- Eli Lilly made up 0.01% of Loomis, Sayles & Company's portfolio in Q1 2026, its #423 holding.
- Loomis, Sayles & Company first reported a position in Eli Lilly in Q4 2013 and has held it in 48 quarters since.
- Loomis, Sayles & Company's Eli Lilly position peaked at $114M in Q2 2014.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.